AR078507A1 - Compuestos lipidicos, composiciones farmaceuticas, usos y metodo de preparacion - Google Patents
Compuestos lipidicos, composiciones farmaceuticas, usos y metodo de preparacionInfo
- Publication number
- AR078507A1 AR078507A1 ARP100101568A ARP100101568A AR078507A1 AR 078507 A1 AR078507 A1 AR 078507A1 AR P100101568 A ARP100101568 A AR P100101568A AR P100101568 A ARP100101568 A AR P100101568A AR 078507 A1 AR078507 A1 AR 078507A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- lipid compound
- compound according
- solvate
- pharmaceutically acceptable
- Prior art date
Links
- -1 LIPID COMPOUNDS Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000002843 carboxylic acid group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/367—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/60—Unsaturated compounds containing ether groups, groups, groups, or groups the non-carboxylic part of the ether being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
- C07C69/68—Lactic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/708—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Un compuesto lipídico caracterizado porque responde a la formula (1) R1-O-C(R2)(R3)-X, donde R1 es un grupo alquilo C10-22, alquenilo C10-22 que tiene 1-6 uniones dobles, o un grupo alquinilo C10-22 que tiene 1-6 uniones triples; R2 y R3 son iguales o diferentes y se seleccionan entre un átomo de hidrogeno, un grupo hidroxi, un grupo alquilo, un átomo de halogeno, un grupo alcoxi, aciloxi, acilo, alquenilo, alquinilo, arilo, alquiltio, alcoxicarbonilo, carboxi, alquilsulfinilo, alquilsulfonilo, amino, y un grupo alquilamino, con la condicion de que R2 y R3 no son ambos un átomo de hidrogeno; o R2 y R3 juntos forman un grupo cicloalquilo; y X es un ácido carboxílico o derivado del mismo, o una sal aceptable farmacéuticamente, solvato, solvato de dicha sal, o una prodroga del mismo. Reivindicacion 41: Una composicion farmacéutica, caracterizada porque comprende al menos un compuesto lipídico de acuerdo con cualquiera de las reivindicaciones 1-40. Reivindicacion 42: Una composicion farmacéutica de acuerdo con la reivindicacion 41, caracterizada porque además comprende un vehículo, excipiente o diluyente farmacéuticamente aceptable, o cualquier combinacion de los mismos. Reivindicacion 71: El uso de al menos un compuesto de acuerdo con cualquiera de las reivindicaciones 1-40, caracterizado porque es para la prevencion o el tratamiento de una inflamacion. Reivindicacion 86: Un método para la produccion de un compuesto lipídico de acuerdo con la reivindicacion 1, caracterizado porque comprende: a) hacer reaccionar R1-OH con (LG)(R3)C(R2)(X), en donde LG es un grupo saliente; y b) aislar el compuesto lipídico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17650309P | 2009-05-08 | 2009-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078507A1 true AR078507A1 (es) | 2011-11-16 |
Family
ID=43050039
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101568A AR078507A1 (es) | 2009-05-08 | 2010-05-07 | Compuestos lipidicos, composiciones farmaceuticas, usos y metodo de preparacion |
| ARP170102752A AR109789A2 (es) | 2009-05-08 | 2017-10-03 | Compuestos lipídicos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102752A AR109789A2 (es) | 2009-05-08 | 2017-10-03 | Compuestos lipídicos |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US8735436B2 (es) |
| EP (1) | EP2427415B1 (es) |
| JP (2) | JP5843755B2 (es) |
| KR (1) | KR101783817B1 (es) |
| CN (1) | CN102459142B (es) |
| AR (2) | AR078507A1 (es) |
| AU (1) | AU2010244136B2 (es) |
| BR (1) | BRPI1015120B8 (es) |
| CA (1) | CA2760877C (es) |
| CL (1) | CL2011002745A1 (es) |
| CO (1) | CO6430454A2 (es) |
| DK (1) | DK2427415T3 (es) |
| EA (1) | EA021177B1 (es) |
| ES (1) | ES2726765T3 (es) |
| HR (1) | HRP20190732T1 (es) |
| IL (1) | IL216171A (es) |
| MA (1) | MA33341B1 (es) |
| MX (2) | MX366137B (es) |
| MY (1) | MY165292A (es) |
| NZ (2) | NZ596386A (es) |
| PH (1) | PH12015500930B1 (es) |
| PL (1) | PL2427415T3 (es) |
| PT (1) | PT2427415T (es) |
| SG (1) | SG175401A1 (es) |
| TR (1) | TR201905768T4 (es) |
| TW (1) | TWI558395B (es) |
| UA (1) | UA109528C2 (es) |
| WO (1) | WO2010128401A1 (es) |
| ZA (2) | ZA201108163B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2733353T3 (es) | 2007-11-09 | 2019-11-28 | Basf As | Compuestos lípidos para uso en productos cosméticos, como suplemento alimenticio o como un medicamento |
| AU2009230718B2 (en) | 2008-03-26 | 2013-07-11 | Oramed Ltd. | Methods and compositions for oral administration of proteins |
| EP2147910A1 (en) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
| NZ596386A (en) | 2009-05-08 | 2014-01-31 | Pronova Biopharma Norge As | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas |
| WO2011051743A1 (en) | 2009-10-30 | 2011-05-05 | Tharos Ltd. | Solvent-free process for obtaining phospholipids and neutral enriched krill oils |
| GB201014633D0 (en) | 2010-09-02 | 2010-10-13 | Avexxin As | Rheumatoid arthritis treatment |
| ES2618604T3 (es) * | 2010-11-05 | 2017-06-21 | Pronova Biopharma Norge As | Métodos de tratamiento usando compuestos lipídicos |
| WO2014083528A2 (en) * | 2012-12-02 | 2014-06-05 | Mahesh Kandula | Compositions and methods for the treatment of cardiovascular diseases and lipid disorders |
| EP2941267B1 (en) | 2013-01-03 | 2022-11-16 | Oramed Ltd. | Compositions for use in treating nafld |
| ES2748562T3 (es) * | 2013-02-28 | 2020-03-17 | Basf As | Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y procedimientos de uso de la misma |
| HUE031763T2 (en) * | 2013-02-28 | 2017-07-28 | Pronova Biopharma Norge As | Process for the preparation of 2 - ((5Z, 8Z, 11Z, 14Z, 17Z) -cosos-5,8,11,14,17-pentaenoxy) -butyric acid \ t |
| GB201409363D0 (en) | 2014-05-27 | 2014-07-09 | Avexxin As | Skin cancer treatment |
| JP2018510206A (ja) * | 2015-04-01 | 2018-04-12 | プロノヴァ バイオファーマ ノルゲ エーエス | アポｃ３を低下させるためのチアオキソ化合物の使用 |
| JP7341916B2 (ja) * | 2015-04-01 | 2023-09-11 | ビーエーエスエフ エーエス | アポｃ３を低下させるためのチアオキソ化合物の使用 |
| KR20240033300A (ko) * | 2015-04-28 | 2024-03-12 | 바스프 에이에스 | 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도 |
| GB201521085D0 (en) * | 2015-11-30 | 2016-01-13 | Biozep As | Use |
| GB201604316D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| CA3037582A1 (en) | 2016-09-21 | 2018-03-29 | Avexxin As | Pharmaceutical composition |
| MX2019013683A (es) | 2017-05-16 | 2020-01-15 | Ability Pharmaceuticals Sl | Una combinacion farmaceutica para el tratamiento de un cancer. |
| JP7312184B2 (ja) * | 2017-10-23 | 2023-07-20 | エピトラッカー インコーポレイテッド | 脂肪酸アナログおよび代謝症候群に関連する症状の処置におけるそれらの使用 |
| CA3084728A1 (en) | 2017-12-06 | 2019-06-13 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| CA3099561A1 (en) * | 2018-05-16 | 2019-11-21 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of conditions related to aging |
| CA3101041A1 (en) * | 2018-05-23 | 2019-11-28 | Northsea Therapeutics B.V. | Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease |
| AU2019274431B2 (en) | 2018-05-23 | 2025-03-13 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity |
| BR112021006907A2 (pt) * | 2018-10-11 | 2021-09-08 | Basf As | Compostos aromáticos e usos farmacêuticos destes |
| WO2020146263A1 (en) | 2019-01-09 | 2020-07-16 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of neurodegenerative diseases |
| WO2020180814A1 (en) | 2019-03-04 | 2020-09-10 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain |
| AU2020320001B2 (en) | 2019-07-29 | 2025-08-21 | Heparegenix Gmbh | Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| JP7639008B2 (ja) | 2020-01-15 | 2025-03-04 | ヘパリジェニックス ゲーエムベーハー | 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼ阻害剤 |
| CN116829139A (zh) | 2020-12-22 | 2023-09-29 | 北海医疗私人有限公司 | 用于治疗非酒精性脂肪性肝炎的包含含氧的结构增强的脂肪酸的联合治疗剂 |
| US12370166B2 (en) | 2021-11-03 | 2025-07-29 | Epitracker, Inc. | Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909554A (en) | 1956-07-23 | 1959-10-20 | Monsanto Chemicals | Process for the manufacture of (alkylmercapto) alkyl sulfates |
| GB1038723A (es) | 1962-03-26 | |||
| US4040781A (en) | 1974-06-06 | 1977-08-09 | Lever Brothers Company | Novel 2-(alkylsulfinyl)ethyl sulfates and compositions employing same |
| US4032564A (en) * | 1974-09-09 | 1977-06-28 | Zoecon Corporation | Esters of cyclopropylalkanols |
| GB1523276A (en) | 1974-09-20 | 1978-08-31 | Lafon Labor | Sulphur-containing amino compounds |
| US4009211A (en) | 1975-07-29 | 1977-02-22 | Gulf Research & Development Company | Beta,beta-dialkylethylmercaptoethoxylate as new compounds |
| US4209410A (en) | 1976-04-28 | 1980-06-24 | Phillips Petroleum Company | Lubricants |
| EP0002007B1 (de) | 1977-11-11 | 1982-07-28 | Ciba-Geigy Ag | Neue Pyridindicarbonsäureesterderivate und ihre Gemische mit metallhaltigen Stabilisatoren sowie ihre Verwendung zur Stabilisierung von chlorhaltigen Thermoplasten |
| JPS5570841A (en) | 1978-11-24 | 1980-05-28 | Konishiroku Photo Ind Co Ltd | Forming method of dye image |
| US4368190A (en) | 1980-04-17 | 1983-01-11 | Merck & Co., Inc. | Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation |
| EP0050327B1 (de) | 1980-10-21 | 1984-06-20 | Roche Diagnostics GmbH | Neue schwefelhaltige Phospholipide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4411808A (en) | 1982-08-04 | 1983-10-25 | Exxon Research & Engineering Co. | Multifunctional additive for power transmission shift fluids |
| US4775223A (en) | 1984-09-20 | 1988-10-04 | Canon Kabushiki Kaisha | Lactic acid derivative, liquid crystal composition containing same and liquid crystal device |
| JPS6176438A (ja) * | 1984-09-20 | 1986-04-18 | Canon Inc | 乳酸誘導体 |
| CA2010000A1 (en) | 1989-04-07 | 1990-10-07 | Paul B. Merkel | Photographic recording material containing a cyan dye-forming coupler |
| JPH0451149A (ja) | 1990-06-19 | 1992-02-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| FR2663928B1 (fr) | 1990-06-27 | 1994-04-08 | Norsolor | Nouveaux composes acryliques soufres, un procede pour leur preparation et leur application a la synthese de nouveaux polymeres. |
| EP0487809A1 (en) | 1990-11-28 | 1992-06-03 | Monsanto Europe S.A./N.V. | Rubber compositions having improved processability and improved rubber-vulcanisate properties |
| JPH0543529A (ja) | 1991-08-10 | 1993-02-23 | Taisho Pharmaceut Co Ltd | アルカンアミドアンモニウム化合物 |
| JP2755279B2 (ja) | 1992-03-19 | 1998-05-20 | 三井化学株式会社 | 熱可塑性樹脂組成物およびその成形体 |
| JP2793458B2 (ja) | 1992-03-19 | 1998-09-03 | 三井化学株式会社 | コネクター用ポリアミド系樹脂組成物およびコネクター |
| EP0702556B1 (en) | 1993-06-10 | 2002-10-23 | Wake Forest University | (phospho)lipids for combatting hepatitis b virus infection |
| JP3110918B2 (ja) | 1993-06-18 | 2000-11-20 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料 |
| US5523430A (en) * | 1994-04-14 | 1996-06-04 | Bristol-Myers Squibb Company | Protein farnesyl transferase inhibitors |
| GB2290789B (en) | 1994-07-01 | 1998-09-16 | Ciba Geigy Ag | Titanium and zirconium complexes of carboxylic acids as corrosion inhibitors |
| DE69524639T2 (de) | 1994-10-13 | 2002-08-08 | Peptech Ltd., North Ryde | Modifizierte mehrfach ungesättigte fettsäuren |
| US7517858B1 (en) | 1995-06-07 | 2009-04-14 | The Regents Of The University Of California | Prodrugs of pharmaceuticals with improved bioavailability |
| FR2741619B1 (fr) | 1995-11-28 | 1998-02-13 | Pf Medicament | Nouveaux derives de 2,3,5-trimethyl-4-hydroxy-anilides, leur preparation et leur application en therapeutique |
| CA2251780A1 (en) * | 1996-04-12 | 1997-10-23 | Peptide Technology Pty. Limited | Methods of treating immunopathologies using polyunsaturated fatty acids |
| EP1019059A4 (en) * | 1997-01-24 | 2004-01-14 | Univ California | USE OF FXR, PPAR-ALPHA AND LXR-ALPHA ACTIVATORS TO RESTORE THE BARRIER FUNCTION, TO PROMOTE EPIDERMIS DIFFERENTIATION, AND TO PROLIFERATE |
| US6060515A (en) * | 1997-01-24 | 2000-05-09 | The Regents Of The University Of California | Treatment of skin conditions by use of PPARα activators |
| AU4806497A (en) * | 1997-10-01 | 1999-04-23 | Procter & Gamble Company, The | Glyoxylic compound comprising one or more active ingredient |
| JPH11180929A (ja) | 1997-12-19 | 1999-07-06 | Asahi Glass Co Ltd | エステル誘導体 |
| WO1999058120A1 (en) | 1998-05-08 | 1999-11-18 | Rolf Berge | USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS |
| FR2786187B1 (fr) | 1998-11-19 | 2001-11-09 | Univ Paris Curie | Composes du type 2-acylamino-2-deoxy-glucono-1,5-lactone, procede d'obtention, compositions les comportant et utilisations |
| FR2792312B1 (fr) | 1999-04-15 | 2001-06-08 | Oreal | Composes (poly)thia-alcynoiques et leurs derives, compositions les comprenant et leur utilisation |
| US6723717B1 (en) | 1999-06-01 | 2004-04-20 | The University Of Texas Southwestern Medical Center | Sulfur-containing thyroxane derivatives and their use as hair growth promotors |
| AR018472A1 (es) | 1999-06-01 | 2001-11-14 | Procter & Gamble | Compuesto, composicion y metodo para el tratamiento de la perdida de cabello |
| NO328803B1 (no) | 2000-03-03 | 2010-05-18 | Thia Medica | Nye fettsyreanaloger |
| IL152979A0 (en) * | 2000-05-26 | 2003-06-24 | Nippon Shinyaku Co Ltd | Heterocyclic compounds |
| UA75083C2 (uk) | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| FR2828487B1 (fr) | 2001-08-09 | 2005-05-27 | Genfit S A | Nouveaux composes derives d'acides gras, preparation et utilisations |
| EP1458354A1 (en) | 2001-12-21 | 2004-09-22 | 3M Innovative Properties Company | Medicinal aerosol formulations comprising ion pair complexes |
| GB2383355A (en) | 2001-12-22 | 2003-06-25 | Schlumberger Holdings | An aqueous viscoelastic fluid containing hydrophobically modified polymer and viscoelastic surfactant |
| AU2003206762C1 (en) | 2002-01-31 | 2009-01-15 | Tfl Ledertechnik Gmbh | Compositions and its use for imparting water repellency to leather or furskins, textiles and other fibrous materials |
| AU2003251518B2 (en) | 2002-06-13 | 2009-07-02 | New York University | Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| FR2845991B1 (fr) | 2002-10-16 | 2005-02-04 | Pf Medicament | Derives d'alpha-phenyl acetanilides et leur application en therapeutique humaine |
| US8372430B2 (en) | 2002-12-17 | 2013-02-12 | The Procter & Gamble Company | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects |
| US20060247458A1 (en) | 2003-02-28 | 2006-11-02 | Shogo Yamamoto | Process for the production of optically active compounds having substituents at the 2-position |
| DE10326303A1 (de) | 2003-06-11 | 2004-12-30 | Celares Gmbh | Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung |
| JP2007522118A (ja) * | 2004-01-30 | 2007-08-09 | ペプリン バイオリピッズ ピーティーワイ エルティーディー | 治療用分子および担体分子 |
| JP4563114B2 (ja) | 2004-08-30 | 2010-10-13 | 出光興産株式会社 | 潤滑剤用添加剤 |
| WO2006109491A1 (ja) | 2005-03-31 | 2006-10-19 | Yamaguchi University | 波力エネルギー変換装置 |
| CN101213281B (zh) * | 2005-05-04 | 2013-03-13 | 普罗诺瓦生物医药挪威公司 | 新的dha衍生物及其作为药物的用途 |
| JP2008540394A (ja) | 2005-05-04 | 2008-11-20 | プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ | 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用 |
| US20070167529A1 (en) | 2006-01-17 | 2007-07-19 | Walton Rebecca A | Antimicrobial compositions for treating fabrics and surfaces |
| ES2391305T3 (es) | 2006-04-12 | 2012-11-23 | Unilever N.V. | Composición oral que comprende un ácido graso poliinsaturado y ácido salicílico para obtener un efecto antiinflamatorio en la piel |
| EP1849449A1 (en) | 2006-04-26 | 2007-10-31 | 3M Innovative Properties Company | Filler containing composition and process for production and use thereof |
| US7763607B2 (en) | 2006-04-27 | 2010-07-27 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators |
| EA200802213A1 (ru) | 2006-05-09 | 2009-10-30 | Химекуэст Фармасьютикалз, Инк. | Способы лечения заболеваний крови |
| MX2009004336A (es) * | 2006-11-01 | 2009-05-22 | Pronova Biopharma Norge As | Lipidos omega-3 alfa-sustituidos que son activadores o moduladores del receptor activado por proliferadores de peroxisoma (ppar). |
| WO2008053340A1 (en) | 2006-11-03 | 2008-05-08 | Pronova Biopharma Norge As | A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent |
| CN101225064A (zh) | 2007-01-19 | 2008-07-23 | 上海汇瑞生物科技有限公司 | 一种制备β-硫杂-α-烷基脂肪酸的新方法 |
| DE102007017179A1 (de) * | 2007-04-12 | 2008-10-23 | Clariant International Ltd. | Verfahren zur Herstellung von Alkylpolyglykolcarbonsäuren und Polyglykoldicarbonsäuren mittels Direktoxidation |
| WO2009046314A2 (en) * | 2007-10-04 | 2009-04-09 | President And Fellows Of Harvard College | Moenomycin analogs, methods of synthesis, and uses thereof |
| US20100267828A1 (en) * | 2007-10-31 | 2010-10-21 | Anne Kristin Holmeide | dha derivatives and their use as medicaments |
| ES2733353T3 (es) | 2007-11-09 | 2019-11-28 | Basf As | Compuestos lípidos para uso en productos cosméticos, como suplemento alimenticio o como un medicamento |
| WO2009149496A1 (en) | 2008-06-10 | 2009-12-17 | Central Northern Adelaide Health Service | Treatment of diabetes and complications thereof and related disorders |
| FR2933006B1 (fr) | 2008-06-27 | 2010-08-20 | Inst Francais Du Petrole | Solution absorbante contenant un inhibiteur de degradation soufre a groupement carboxyle et methode pour limiter la degradation d'une solution absorbante |
| PL2315740T3 (pl) | 2008-07-08 | 2018-05-30 | Catabasis Pharmaceuticals, Inc. | Salicylany acetylowane kwasem tłuszczowym i ich zastosowania |
| EP2147910A1 (en) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
| NZ596386A (en) * | 2009-05-08 | 2014-01-31 | Pronova Biopharma Norge As | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas |
| BR112012004677A2 (pt) | 2009-09-01 | 2020-11-03 | Catabasis Pharmaceuticals, Inc. | conjugados de ácido graxo niacina e seus usos |
| US20130046013A1 (en) | 2010-01-20 | 2013-02-21 | Ragnar Hovland | Salicylate fatty acid derivatives |
| ES2618604T3 (es) | 2010-11-05 | 2017-06-21 | Pronova Biopharma Norge As | Métodos de tratamiento usando compuestos lipídicos |
| WO2012115695A1 (en) | 2011-02-25 | 2012-08-30 | Catabasis Pharmaceuticals, Inc. | Bis-fatty acid conjugates and their uses |
| WO2013016531A2 (en) | 2011-07-26 | 2013-01-31 | Purdue Research Foundation | Compounds and methods for use in treating neoplasia and cancer |
-
2010
- 2010-05-07 NZ NZ596386A patent/NZ596386A/en unknown
- 2010-05-07 KR KR1020117028820A patent/KR101783817B1/ko active Active
- 2010-05-07 JP JP2012509111A patent/JP5843755B2/ja active Active
- 2010-05-07 CA CA2760877A patent/CA2760877C/en active Active
- 2010-05-07 EA EA201171371A patent/EA021177B1/ru not_active IP Right Cessation
- 2010-05-07 PL PL10772077T patent/PL2427415T3/pl unknown
- 2010-05-07 WO PCT/IB2010/001251 patent/WO2010128401A1/en not_active Ceased
- 2010-05-07 MY MYPI2011005299A patent/MY165292A/en unknown
- 2010-05-07 TW TW099114670A patent/TWI558395B/zh active
- 2010-05-07 MX MX2014000881A patent/MX366137B/es unknown
- 2010-05-07 EP EP10772077.3A patent/EP2427415B1/en active Active
- 2010-05-07 MA MA34421A patent/MA33341B1/fr unknown
- 2010-05-07 NZ NZ618734A patent/NZ618734A/en unknown
- 2010-05-07 DK DK10772077.3T patent/DK2427415T3/da active
- 2010-05-07 HR HRP20190732TT patent/HRP20190732T1/hr unknown
- 2010-05-07 BR BRPI1015120A patent/BRPI1015120B8/pt active IP Right Grant
- 2010-05-07 PT PT10772077T patent/PT2427415T/pt unknown
- 2010-05-07 AU AU2010244136A patent/AU2010244136B2/en active Active
- 2010-05-07 AR ARP100101568A patent/AR078507A1/es active IP Right Grant
- 2010-05-07 SG SG2011079613A patent/SG175401A1/en unknown
- 2010-05-07 US US13/319,101 patent/US8735436B2/en active Active
- 2010-05-07 CN CN201080030436.5A patent/CN102459142B/zh active Active
- 2010-05-07 TR TR2019/05768T patent/TR201905768T4/tr unknown
- 2010-05-07 ES ES10772077T patent/ES2726765T3/es active Active
- 2010-05-07 MX MX2011011614A patent/MX2011011614A/es active IP Right Grant
- 2010-07-05 UA UAA201113181A patent/UA109528C2/ru unknown
-
2011
- 2011-11-04 CL CL2011002745A patent/CL2011002745A1/es unknown
- 2011-11-07 IL IL216171A patent/IL216171A/en active IP Right Grant
- 2011-11-07 ZA ZA2011/08163A patent/ZA201108163B/en unknown
- 2011-12-07 CO CO11168717A patent/CO6430454A2/es active IP Right Grant
-
2013
- 2013-05-30 ZA ZA2013/03962A patent/ZA201303962B/en unknown
-
2014
- 2014-04-11 US US14/250,980 patent/US20140221439A1/en not_active Abandoned
-
2015
- 2015-04-24 PH PH12015500930A patent/PH12015500930B1/en unknown
- 2015-07-31 JP JP2015151385A patent/JP2016026146A/ja active Pending
-
2017
- 2017-10-03 AR ARP170102752A patent/AR109789A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078507A1 (es) | Compuestos lipidicos, composiciones farmaceuticas, usos y metodo de preparacion | |
| CR20220281A (es) | Derivados de pirazolilo útiles como agentes anti-cancerígenos | |
| CU20110235A7 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| CY1119727T1 (el) | Ενωσεις και συνθεσεις για τη θεραπεια παρασιτικων νοσων | |
| SV2011004077A (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
| NO20080865L (no) | Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer | |
| TR201802944T4 (tr) | İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇ | |
| CO6690768A2 (es) | Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7 | |
| CY1120826T1 (el) | Τριυποκατεστημενα παραγωγα βενζοτριαζολης ως αναστολεις διϋδροοροτικης οξυγενασης | |
| CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| UY33075A (es) | Derivados de ciclohexano y usos de los mismos | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| CY1118541T1 (el) | D2 αποκλειστες, μεθοδοι συνθεσης και μεθοδοι χρησης | |
| EA201200471A1 (ru) | Простые эфирные производные бициклических гетероарилов | |
| PH12015501752B1 (en) | Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors | |
| EP2581372A4 (en) | CYANOCHINOLINDERIVATE | |
| MX378555B (es) | Proceso para la preparacion de derivados del acido biliar de las sulfonilureas | |
| CY1119710T1 (el) | Συντηγμενες θειαζολο- και οξαζολο-πυριμιδινονες | |
| EA201391524A1 (ru) | Производные гликозида и их применение | |
| ECSP10010597A (es) | Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas | |
| AR077429A1 (es) | Compuestos hidroxiasenapina sus derivados y composiciones farmaceuticas que comprenden los mismos | |
| CL2019003467A1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |